In this review, we focus on CD8+ TRM cells accumulating in human solid tumors, mainly non-small-cell lung carcinoma (NSCLC), and current insight implicating CD103 integrin in regulating TRM functions and CTL-mediated antitumor immune responses, with potential prognosis and immunotherapeutic applications. This evidence concerns the gene CD8A and non-small cell lung carcinoma.